Buprenorphine: blending practice and research

Ling, Walter; Smith, David Eugene

doi:10.1016/s0740-5472(02)00257-x

Cited by 62 publications

(45 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…demonstrated its safety (Ling & Smith, 2002;Walsh & Eissenberg, 2003), its role in reducing opioid withdrawal symptoms (Bickel & Amass, 1995;Chadderton, 2000), and its effectiveness in reducing opioid use (Fiellin et al, 2008;Fudala et al, 2003). Buprenorphine is primarily marketed as Suboxone ® (Reckitt Benckiser Pharmaceuticals, Richmond, VA) and, more recently, as Zubsolv ® (Orexo US, Morristown, NJ); both products combine buprenorphine and naloxone in sublingual formulations.…”

mentioning

confidence: 99%

The Supply of Physicians Waivered to Prescribe Buprenorphine for Opioid Use Disorders in the United States: A State-Level Analysis

Knudsen

2015

J. Stud. Alcohol Drugs

View full text Add to dashboard Cite

mentioning

confidence: 99%

The Supply of Physicians Waivered to Prescribe Buprenorphine for Opioid Use Disorders in the United States: A State-Level Analysis

Knudsen

2015

J. Stud. Alcohol Drugs

View full text Add to dashboard Cite

“…Buprenorphine, a partial mu-receptor opiate agonist [25], differs significantly from full agonists. Most significantly, buprenorphine has a plateau of its agonist properties at higher doses resulting in an improved safety profile compared with a full agonist.…”

Section: Buprenorphinementioning

confidence: 99%

International Expansion of the Use of Pharmacotherapies for the Treatment of Opioid Dependence

Kresina¹

2012

Clinic Experiment Pharmacol

View full text Add to dashboard Cite

Until recently, the global availability and consumption of opioid agonists and psychotropic medications have been below the levels needed for research to demonstrate local efficacy and to develop local evidence-based best medical practices. In addition, the global availability and use of opioid agonists and psychotropic medications have not been sufficient to implement the well documented efficacy shown for the treatment of opioid dependence that has been developed by research over the last 40 years. This strong research base has resulted in the development of evidencebased medical practices, such as Medication Assisted Treatment (MAT) for opioid dependence. The recognition of MAT as an effective medical treatment for opioid abuse and dependence has resulted in a substantial global increase in the medical use of opioid agonists and psychotropic medications to address opioid dependence. This increase is particularly evident in the initiation of new MAT programs in regions of Europe, North America, Africa, Asia and Oceania. While in other regions of the world, the medical use of opioid agonists and psychotropic medications have not substantially increased, the implementation of MAT programs have begun as part of the global effort to reduce HIV/AIDS. These HIV prevention programs have utilized MAT as an element of programs that target injection drug users to reduce their risk of both acquiring and transmitting HIV infection. Thus, this article documents the recent international expansion of the use of MAT for opioid dependence as a result of efforts to increase access and availability of evidence based treatments for opioid dependence as well as efforts to reduce the spread of infectious diseases, such as HIV/AIDS.

show abstract

“…However, in the United States, buprenorphine-only OTPs have been recently developed where buprenorphine is provided to opioid dependent patents under the highly regulated rules and regulations that apply to methadone. Buprenorphine, a partial mu-receptor opiate agonist (Ling & Smith 2002), differs significantly from full agonists. Most significantly, buprenorphine has a plateau of its agonist properties at higher doses.…”

Section: Medication Assited Treatment Utilizing Buprenorphinementioning

confidence: 99%

Substance Abuse Treatment Utilizing Medication Assisted Treatment as HIV Prevention

Kresina¹,

Lubran²,

Cheever³

2011

Recent Translational Research in HIV/AIDS

View full text Add to dashboard Cite

Buprenorphine: blending practice and research

Cited by 62 publications

References 19 publications

The Supply of Physicians Waivered to Prescribe Buprenorphine for Opioid Use Disorders in the United States: A State-Level Analysis

The Supply of Physicians Waivered to Prescribe Buprenorphine for Opioid Use Disorders in the United States: A State-Level Analysis

International Expansion of the Use of Pharmacotherapies for the Treatment of Opioid Dependence

Substance Abuse Treatment Utilizing Medication Assisted Treatment as HIV Prevention

Contact Info

Product

Resources

About